Accès ouvert déclaré 2019 article

Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors

Mohammad I. Abu Zaid, Paul C. Dinh, Patrick O. Monahan, Chunkit Fung, Omar El-Charif, Darren Richard Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra K. Althouse, Shirin Ardeshir‐Rouhani‐Fard, Howard D. Sesso, Robert Anthony Huddart, Taisei Mushiroda, Michiaki Kubo, M. Eileen Dolan, Lawrence H. Einhorn, Sophie D. Fosså, Lois B. Travis

22Citations signalées, ce qui n’est pas une note de qualité

15Institutions déclarées

5Pays d’affiliation déclarés

Rattachement africain : us, ca, gb, jp, no. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern platinum-based chemotherapy. PATIENTS AND METHODS: Eligible TCS were <55 years of age at diagnosis and treated with first-line platinum-based chemotherapy. Participants underwent physical examinations and completed questionnaires regarding 15 AHOs and health behaviors. Hypogonadism was defined as serum testosterone levels ≤3.0 ng/mL or use of testosterone replacement therapy. We investigated the role of 2 single nucleotide polymorphisms (rs6258 and rs12150660) in the sex hormone-binding globulin (SHBG) locus implicated in increased hypogonadism risk in the general population. RESULTS: Of 491 TCS (median age at assessment, 38.2 years; range, 18.7-68.4 years), 38.5% had hypogonadism. Multivariable binary logistic regression analysis identified hypogonadism risk factors, including age at clinical evaluation (odds ratio [OR], 1.42 per 10-year increase; P= .006) and body mass index of 25 to <30 kg/m2 (OR, 2.08; P= .011) or ≥30 kg/m2 (OR, 2.36; P= .005) compared with <25 kg/m2. TCS with ≥2 risk alleles for the SHBG SNPs had a marginally significant increased hypogonadism risk (OR, 1.45; P= .09). Vigorous-intensity physical activity appeared protective (OR, 0.66; P= .07). Type of cisplatin-based chemotherapy regimen and socioeconomic factors did not correlate with hypogonadism. Compared with TCS without hypogonadism, those with hypogonadism were more likely to report ≥2 AHOs (65% vs 51%; P= .003), to take medications for hypercholesterolemia (20.1% vs 6.0%; P<.001) or hypertension (18.5% vs 10.6%; P= .013), and to report erectile dysfunction (19.6% vs 11.9%; P= .018) or peripheral neuropathy (30.7% vs 22.5%; P= .041). A marginally significant trend for increased use of prescription medications for either diabetes (5.8% vs 2.6%; P= .07) or anxiety/depression (14.8% vs 9.3%; P= .06) was observed. CONCLUSIONS: At a relatively young median age, more than one-third of TCS have hypogonadism, which is significantly associated with increased cardiovascular disease risk factors, and erectile dysfunction. Providers should screen TCS for hypogonadism and treat symptomatic patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors
Date Crossref: 01/05/2019
Éditeur: Harborside Press, LLC
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Indiana University Health Bone Marrow and Blood Stem Cell Transplantation pays non établi dans la notice
Établissement de santé
Indiana University – Purdue University Indianapolis pays non établi dans la notice
Université ou école supérieure
University of Rochester Medicine pays non établi dans la notice
Établissement de santé
University of Chicago cDepartment of Medicine pays non établi dans la notice
Université ou école supérieure
Memorial Sloan Kettering Cancer Center pays non établi dans la notice
Établissement de santé
Princess Margaret Cancer Centre pays non établi dans la notice
Établissement de santé
University of Pennsylvania fDepartment of Medicine pays non établi dans la notice
Université ou école supérieure
Brigham and Women's Hospital Department of Medicine pays non établi dans la notice
Établissement de santé
Dana-Farber Cancer Institute gDepartment of Radiation Oncology pays non établi dans la notice
Structure de recherche
Dana-Farber Brigham Cancer Center pays non établi dans la notice
Établissement de santé
Indiana Cancer Consortium pays non établi dans la notice
Organisation à but non lucratif
Platinum Group Coatings (United States) pays non établi dans la notice
Entreprise

Bone Marrow and Blood Stem Cell Transplantation — Indiana University Health, Indiana University – Purdue University Indianapolis et University of Rochester Medicine, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Hormonal and reproductive studiesMenopause: Health Impacts and TreatmentsTesticular diseases and treatments

Lire en accès ouvert Consulter la publication primaire Ouvrir le DOI